All In Biotech

Drug Trial Radar · NCT06541691

Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease

Coated or Chewable Aspirin in Patients with Established Atherosclerotic Disease and a Hybrid Strategy to Mitigate the Adverse Effects of Air Pollution: the COATED-AIR Randomized Clinical Trial

Last checked: Nov 19, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 3,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,000

Planned (sponsor's estimate)

Start

Mar 6, 2024

Primary completion

Mar 30, 2026

Study completion Mar 30, 2027

Sponsor

Lead sponsor
Rajaie Cardiovascular Medical and Research CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Brigham and Women's Hospital
First posted
Aug 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Although both enteric-coated and plain formulations of aspirin are being used commonly, there are no high-quality comparisons between these formulations with respect to clinical efficacy outcomes in patients with atherosclerotic cardiovascular diseases (ASCVD). Air pollution is also a major contributor to the excess risk of cardiovascular events in many regions of the world. However, little is known about the effect of individual-level mitigation strategies against air pollution in reducing cardiovascular outcomes. The purpose of the first randomization is to compare the efficacy and safety of enteric-coated versus plain low-dose (81 mg) aspirin formulations in a double-blind fashion. The second randomization compares a multifaceted intervention including one-page educational flashcard, cell phone text messages alerting participants on polluted days, recommending them to stay indoors or wear KN-95 facemasks provided by the study team in case of necessary outdoor activity, and recommendation to consume citrus fruits on polluted days versus usual care. Both randomization are powered for clinical outcomes and the results will inform practice.

Conditions

  • Atherosclerotic Cardiovascular Disease
  • Coronary Artery Disease
  • Ischemic Heart Disease
  • Ischemic Stroke
  • Peripheral Arterial Disease
  • Carotid Artery Stenosis
  • Carotid Atherosclerosis

Interventions

  • Enteric-coated aspirinDrug

    Enteric-coated aspirin tablet 81 mg, once daily

  • Plain aspirinDrug

    Plain aspirin tablet 81 mg, once daily

  • Hybrid strategyOther

    A hybrid strategy composed from: * A one-page educational flashcard * Alerting patients on highly polluted days via text message * Encouraging patients to stay at home or minimizing outdoor activity on highly polluted days * Encouraging patients via text message to wear KN-95 facemasks (provided by the investigators of this study) during outdoors time on highly polluted days * Encouraging patients to consume citrus fruits during highly polluted days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of fatal or nonfatal ischemic stroke (not deemed to be related to systemic hypotension), type I myocardial infarction, and acute limb eventsTime frame: within maximum of 30-month follow-up
  2. Composite of non-fatal ischemic stroke (not deemed to be related to systolic hypotension), type I myocardial infarction, acute limb events, or cardiovascular deathTime frame: within maximum of 30-month follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rajaie Cardiovascular Medical and Research Center

    Tehran, Tehran Province, Iran · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.